Editorial Research Topic: Non-coding RNA as Therapeutic Target: A Game Changer in Cardiac Regenerative Strategies?

Background: CASC15, one of long non-coding RNA, is involved in the regulation of many tumor biological processes, and is expected to become a new biological therapeutic target. This paper aims to elucidate the pathophysiological function of CASC15 in various tumors. Methods: The relationship between CASC15 and tumors was analyzed by searching references, and summarizes the specific pathophysiological mechanism of CASC15. Results: LncRNA CASC15 is closely related to tumor development, and has been shown to be abnormally high expressed in all kinds of tumors, including breast cancer, cervical cancer, lung cancer, hepatocellular carcinoma, gastric cancer, bladder cancer, colon cancer, colorectal cancer, cardiac hypertrophy, intrahepatic cholangiocarcinoma, leukemia, melanoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma. However, CASC15 has been found to be downexpressed abnormally in ovarian cancer, glioma and neuroblastoma. Besides, it is identified that CASC15 can affect the proliferation, invasion and apoptosis of tumors. Conclusion: LncRNA CASC15 has the potential to become a new therapeutic target or marker for a variety of tumors.

Download Full-text

Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma

Experimental and Molecular Pathology ◽

10.1016/j.yexmp.2021.104638 ◽

2021 ◽

pp. 104638

Author(s):

Chao Guo ◽

Shuhuang Zhou ◽

Weimin Yi ◽

Pingzhou Yang ◽

Ou Li ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Therapeutic Target ◽

Antisense Rna ◽

Prognostic Biomarker ◽

Non Coding Rna ◽

Long Non Coding Rna

Download Full-text

Long non-coding RNA (lncRNA): A potential therapeutic target in acute lung injury

Genes & Diseases ◽

10.1016/j.gendis.2021.07.004 ◽

2021 ◽

Author(s):

Almaz Zaki ◽

M Shadab Ali ◽

Vijay Hadda ◽

Syed Mansoor Ali ◽

Anita Chopra ◽

...

Keyword(s):

Acute Lung Injury ◽

Lung Injury ◽

Therapeutic Target ◽

Potential Therapeutic Target ◽

Non Coding Rna ◽

Long Non Coding Rna

Download Full-text

MiR-29a: a potential therapeutic target and promising biomarker in tumors

Bioscience Reports ◽

10.1042/bsr20171265 ◽

2018 ◽

Vol 38 (1) ◽

Cited By ~ 10

Author(s):

Jin-yan Wang ◽

Qian Zhang ◽

Dan-dan Wang ◽

Wei Yan ◽

Huan-huan Sha ◽

...

Keyword(s):

Cell Proliferation ◽

Therapeutic Target ◽

Therapeutic Strategy ◽

Transcriptional Level ◽

Additional Insight ◽

Potential Therapeutic Target ◽

Rna Molecules ◽

Non Coding Rna ◽

Non Coding Rnas ◽

Novel Therapeutic

MiRNAs, small non-coding RNA molecules, were recognized to be associated with the incidence and development of diverse neoplasms. MiRNAs were small non-coding RNAs that could regulate post-transcriptional level by binding to 3′-UTR of target mRNAs. Amongst which, miR-29a was demonstrated that it had significant impact on oncogenicity in various neoplasms through binding to critical genes which enhanced or inhibited the progression of cancers. MiR-29a participated in kinds of physiological and pathological processes, including virus replication, cell proliferation, differentiation, apoptosis, fibrosis, angiogenesis, tumorigenicity, metastasis, drug-resistance, and so on. According to its sufficient sensitivity and specificity, many studies showed that miR-29a might serve as a potential therapeutic target and promising biomarker in various tumors. In this review, we discussed the functions of miR-29a and its potential application in the diagnosis, treatment and stages of carcinoma, which could provide additional insight to develop a novel therapeutic strategy.

Download Full-text

ADAMTS9-AS2: A functional long non-coding RNA in tumorigenesis

Current Pharmaceutical Design ◽

10.2174/1381612827666210325105106 ◽

2021 ◽

Vol 27 ◽

Author(s):

Wen Xu ◽

Bei Wang ◽

Yuxuan Cai ◽

Jinlan Chen ◽

Xing Lv ◽

...

Keyword(s):

Dna Methylation ◽

Signaling Pathways ◽

Therapeutic Target ◽

Molecular Mechanisms ◽

Human Cancer ◽

Migration Inhibition ◽

Cancer Proliferation ◽

Non Coding Rna ◽

Non Coding Rnas ◽

Long Non Coding Rna

Background: Long non-coding RNAs (lncRNA) have been identified as novel molecular regulators in cancers. LncRNA ADAMTS9-AS2 can mediate the occurrence and development of cancer through various ways such as regulating miRNAs, activating the classical signaling pathways in cancer, and so on, which have been studied by many scholars. In this review, we summarize the molecular mechanisms of ADAMTS9-AS2 in different human cancers. Methods: Through a systematic search of PubMed, lncRNA ADAMTS9-AS2 mediated molecular mechanisms in cancer are summarized inductively. Results: ADAMTS9-AS2 aberrantly expression in different cancers is closely related to cancer proliferation, invasion, migration, inhibition of apoptosis. The involvement of ADAMTS9-AS2 in DNA methylation, mediating PI3K / Akt / mTOR signaling pathways, regulating miRNAs and proteins, and such shows its significant potential as a therapeutic cancer target. Conclusion: LncRNA ADAMTS9-AS2 can become a promising biomolecular marker and a therapeutic target for human cancer.

Download Full-text

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements

Haematologica ◽

10.3324/haematol.2021.276048 ◽

2021 ◽

Author(s):

Sarah Grasedieck ◽

Ariene Cabantog ◽

Liam MacPhee ◽

Junbum Im ◽

Christoph Ruess ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Therapeutic Target ◽

Myeloid Leukemia ◽

Integration Site ◽

Retinoic Acid Receptor ◽

Aberrant Expression ◽

Interacting Protein ◽

Disease Subtype ◽

Non Coding Rna ◽

Acute Myeloid

Aberrant expression of Ecotropic Viral Integration Site 1 (EVI1) is a hallmark of acute myeloid leukemia (AML) with inv(3) or t(3;3), which is a disease subtype with especially poor outcome. In studying transcriptomes from AML patients with chromosome 3q rearrangements, we identified a significant upregulation of the Nuclear Receptor Interacting Protein 1 (NRIP1) as well as its adjacent non-coding RNA LOC101927745. Utilizing transcriptomic and epigenomic data from over 900 primary patient samples as well as genetic and transcriptional engineering approaches, we have identified several mechanisms that can lead to upregulation of NRIP1 in AML. We hypothesize that the LOC101927745 transcription start site harbors a context-dependent enhancer that is bound by EVI1, causing upregulation of NRIP1 in AML with chr3 abnormalities. Furthermore, we show that NRIP1 knockdown negatively affects the proliferation and survival of 3q-rearranged AML cells and increases their sensitivity towards ATRA, suggesting that NRIP1 is relevant for the pathogenesis of inv(3)/t(3;3) AML and could serve as a novel therapeutic target in myeloid malignancies with 3q abnormalities.

Download Full-text